Aratana Therapeutics Inc. (NASDAQ:PETX)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Group in a research note issued to investors on Friday. They currently have a $11.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $13.00. Jefferies Group’s price target suggests a potential upside of 41.21% from the stock’s current price.

A number of other brokerages also recently commented on PETX. Barclays PLC lowered their price target on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, August 11th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $11.00 price target on shares of Aratana Therapeutics in a report on Wednesday, August 10th. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. William Blair reaffirmed an “outperform” rating on shares of Aratana Therapeutics in a report on Wednesday, August 17th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Aratana Therapeutics in a report on Tuesday, September 6th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Aratana Therapeutics has a consensus rating of “Buy” and an average target price of $10.71.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) opened at 7.79 on Friday. The stock’s market cap is $288.57 million. The firm’s 50 day moving average price is $8.52 and its 200-day moving average price is $7.82. Aratana Therapeutics has a 12-month low of $2.56 and a 12-month high of $10.73.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.10. Aratana Therapeutics had a negative net margin of 60.32% and a negative return on equity of 19.87%. During the same period in the prior year, the business posted ($1.58) earnings per share. Equities research analysts anticipate that Aratana Therapeutics will post ($0.72) earnings per share for the current fiscal year.

In other news, insider Craig A. Tooman sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, September 9th. The shares were sold at an average price of $9.25, for a total transaction of $277,500.00. Following the transaction, the insider now directly owns 72,424 shares of the company’s stock, valued at $669,922. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ernst Heinen sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $10.00, for a total transaction of $100,000.00. Following the transaction, the insider now directly owns 115,494 shares in the company, valued at $1,154,940. The disclosure for this sale can be found here. Insiders own 6.70% of the company’s stock.

Several institutional investors have recently modified their holdings of PETX. Iguana Healthcare Management LLC bought a new position in shares of Aratana Therapeutics during the first quarter worth approximately $1,070,000. Blair William & Co. IL raised its position in shares of Aratana Therapeutics by 9.8% in the second quarter. Blair William & Co. IL now owns 603,652 shares of the biopharmaceutical company’s stock valued at $3,815,000 after buying an additional 53,703 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Aratana Therapeutics by 9.7% in the second quarter. California State Teachers Retirement System now owns 69,941 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 6,211 shares during the last quarter. General American Investors Co. Inc. acquired a new position in shares of Aratana Therapeutics during the second quarter valued at about $2,604,000. Finally, Tocqueville Asset Management L.P. raised its position in shares of Aratana Therapeutics by 51.5% in the third quarter. Tocqueville Asset Management L.P. now owns 50,000 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 17,000 shares during the last quarter. 81.86% of the stock is currently owned by institutional investors and hedge funds.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.